JAK/STAT signaling
Subcategories of "JAK/STAT signaling"
Found 354 products of "JAK/STAT signaling"
Prohibitin ligand 1
Compound 22i, a prohibitin ligand, protects the heart at nanomolar levels by inducing STAT3 phosphorylation.Formula:C20H22N2OColor and Shape:SolidMolecular weight:306.4STAT3-IN-36
CAS:STAT3-IN-36 (compound 11g) is a tritarget inhibitor that selectively targets LRPPRC, STAT3, and CDK1, exhibiting potent anticancer activity. This compound binds to LRPPRC, STAT3, and CDK1, demonstrating more effective anticancer effects than those of TMF or Capecitabine. Additionally, STAT3-IN-36 exhibits an IC50 value of 1.8 μM in HGC27 cells.Formula:C30H24F2N2O9S2Color and Shape:SolidMolecular weight:658.65(3S,4R)-Tofacitinib
CAS:(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM).Formula:C16H20N6OPurity:98%Color and Shape:SolidMolecular weight:312.37SI-109
CAS:SI-109 is a potent inhibitor of STAT3 SH2 domain (Ki=9 nM),and with antitumor activity.Formula:C40H44F2N7O9PPurity:98%Color and Shape:SolidMolecular weight:835.79Londamocitinib
CAS:Londamocitinib (JAK1-IN-7) is a selective and potent JAK1 inhibitor with anti-inflammatory activity.Formula:C28H31F2N7O4SPurity:98.64% - 99.56%Color and Shape:SolidMolecular weight:599.65Ref: TM-T11706
1mg170.00€5mg416.00€10mg567.00€25mg858.00€50mg1,108.00€100mg1,485.00€1mL*10mM (DMSO)537.00€JDTic
CAS:JDTic, a 4-phenylpiperidine derivative distantly related to analgesics like meperidine and ketobemidone and more closely to the mu opioid antagonist alvimopan, exhibits a notably long duration of action, maintaining effects in animals for weeks following a single dose. This duration is not due to irreversible binding to the kappa opioid receptor but rather to altered activity of c-Jun N-terminal kinases. As a highly selective antagonist for the κ-opioid receptor, without influencing the μ- or δ-opioid receptors, JDTic has shown potential in animal studies for producing antidepressant and anxiolytic effects. It also demonstrates promise in treating addiction to substances such as cocaine and morphine, distinguishing itself structurally from other kappa antagonists like norbinaltorphimine.Formula:C28H39N3O3Color and Shape:SolidMolecular weight:465.63(3R,4S)-Tofacitinib
CAS:(3R,4S)-Tofacitinib, the less active enantiomer of Tofacitinib, is a JAK3 inhibitor with an IC50 of 1 nM.Formula:C16H20N6OPurity:98%Color and Shape:SolidMolecular weight:312.37JAK2-IN-9
CAS:Compound A8, known as JAK2-IN-9, is a selective JAK2 inhibitor with an IC50 of 5 nM.
Formula:C20H24N6O2SPurity:98%Color and Shape:SolidMolecular weight:412.51DPP
CAS:DPP, a Platinum(IV) complex with a pterostilbene-derived axial ligand, inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, demonstrating
Formula:C36H40Cl2N2O10PtPurity:98%Color and Shape:SolidMolecular weight:926.7JAK-IN-34
CAS:JAK-IN-34 (compound 11n) is a potent inhibitor of Janus kinases (JAKs), demonstrating IC50 values of 0.40 nM for JAK1, 0.83 nM for JAK2, 2.10 nM for JAK3,
Formula:C27H26N6OPurity:98%Color and Shape:SolidMolecular weight:450.53STAT3-IN-18
CAS:STAT3-IN-18 (compound SPP), a platinum (IV) complex featuring an axial ligand from sandalwood, suppresses the JAK2-STAT3 pathway in breast cancer (BC) cells and
Formula:C18H24Cl2N2O6PtPurity:98%Color and Shape:SolidMolecular weight:630.38JAK1-IN-11
CAS:JAK1-IN-11 (compound 11) serves as a potent inhibitor of Janus kinases, exhibiting nanomolar inhibitory concentrations with IC50 values of 0.02 nM (JAK1) and 0.
Formula:C26H36N6O4SPurity:98%Color and Shape:SolidMolecular weight:528.67JAK1-IN-10
CAS:JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, functions as a potent and selective inhibitor of JAK1 [1].
Formula:C15H17N7Purity:98%Color and Shape:SolidMolecular weight:295.34JAK-IN-27
CAS:JAK-IN-27, also known as compound 1, is an orally active, potent inhibitor of the JAKS family kinases, displaying inhibitory concentrations (IC50s) of 3.0 nM
Formula:C20H21F2N7OPurity:98%Color and Shape:SolidMolecular weight:413.42
